Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VX-445 triple combination therapy in cystic fibrosis with F508del/minimal function genotype
2018-000183-28Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change in percent predicted FEV1 from baseline through Week 24. Started Jun 2018; status: completed.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-000183-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000183-28.